Latest news

• Novartis’ Promacta receives US breakthrough therapy designation

  Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a

• CHMP backs orphan drugs Uptravi and Coagadex

  new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

• Novartis bags EU approvals for three ex-GSK drugs

  Novartis bags EU approvals for three ex-GSK drugs. Revolade, Tafinlar and Mekinist all receive regulatory approval. ... The Swiss company announced this morning that platelet-boosting drug Revolade (eltrombopag) has become the first approved drug in the

• EMA recommends two AbbVie treatments for hepatitis C

  Over the last year, the EMA has recommended marketing authorisations for four new medicines for the treatment of HCV, including GSK's Revolade (eltrombopag) and Janssen's Olysio (simeprevir).

• GSK files Promacta for anaemia indication in US

  Outside the US, the drug is known as Revolade.